secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verona Pharma plc (—)
CIK:        0001657312
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001104659-24-000015
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 1.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verona Pharma secures up to $400M debt facility for planned launch of ensifentrine
--------------------------------------------------------------------------------

- Drew $50M at closing; additional $100M available upon FDA approval of ensifentrine (PDUFA June 26, 2024).
- Up to $150M in two tranches subject to net sales milestones; $100M discretionary for strategic initiatives.
- 53-month interest-only period, then 7-month amortization; final payment fee 2.50%-3.50%.
- Replaces existing $150M facility with Oxford; $20M outstanding repaid plus prepayment costs.
- Non-dilutive capital to support commercial launch; lenders: Oxford Finance and Hercules Capital (HTGC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1657312/000110465924000015/0001104659-24-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1657312/000110465924000015/tm2333838d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer